Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide and Thalidomide in Refractory Multiple Myeloma
NCT00193544Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Mar 2002
- Primary completion
- Oct 2005
- Modality
- DNA Intercalators/Alkylators
01
Overview
A Phase 2 trial of arsenic trioxide in multiple myeloma (MM), sponsored by SCRI Development Innovations. Started Mar 2002; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00193544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193544.